Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Randomised Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma

NCT02544308 is registered in ClinicalTrials.gov with University College, London as lead sponsor.

NCT NCT02544308
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02544308 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Randomised Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma
Lead sponsor
University College, London
Phase
Phase 3
Overall status
Active, not recruiting
Start date
March 10, 2017
Completion date
December 31, 2026
Enrollment
36 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

plasmacytoma